By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Alzheimer’s Drug Development: An Avant-Garde Approach
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Alzheimer’s Drug Development: An Avant-Garde Approach
Medical InnovationsSpecialties

Alzheimer’s Drug Development: An Avant-Garde Approach

Deanna Pogorelc
Deanna Pogorelc
Share
3 Min Read
SHARE

alzheimer's disease

Originally published on MedCityNews.com.

alzheimer's disease

Originally published on MedCityNews.com.

More Read

dental care
Dental Implants vs Veneer: Which Is Best For You?
Imaging Tests Available Stat! The Blame Game Isn’t Necessary
How Does Occupational Therapy Help Kids with Autism?
Study Shows Solid Longterm Outcomes with MRgFUS for Uterine Fibroids
Predictors of Hospitalization in Congestive Heart Failure Patients

A handful of high-profile Alzheimer’s disease drugs have failed in late-stage clinical trials in the last year — at least two of them based on the hypothesis that buildup of amyloid plaques in the brain give rise to neurodegeneration. Startup T3D Therapeutics Inc. thinks that warrants a different approach to a disease-altering therapeutic.

“Alzheimer’s disease involves multiple abnormalities, yet the pharmaceutical industry has placed heavy bets on developing treatments for just one abnormality,” said founder and CEO John Didsbury.

T3D claims it’s developing a drug with the potential to address several disease pathologies, including beta-amyloid plaque issues, inflammation, neuronal cell loss, neurotransmitter deficits, insulin deficiency and tau neurofibrillary tangles. And it would come in the form of a once-a-day pill for people with mild to moderate Alzheimer’s.

The Durham, North Carolina company licensed its technology from specialty pharmaceutical company DARA BioSciences, where Didsbury formerly served as president and chief operating officer. DARA had developed the drug candidate, now called T3D-959, through Phase I clinical trials as a treatment for diabetes and dyslipidemia. Thus, Didsbury said a key piece of T3D’s approach to altering the course of Alzheimer’s is insulin regulation.

Researchers have been studying a link between insulin dysregulation and Alzheimer’s for almost a decade. T3D sees insulin deficiency as a trigger for the abnormalities that lead to neurodegeneration.

“Clinical symptoms never occur without sugar metabolism decreases in the brain, which results from neurons becoming resistant to insulin,” he said. “Without the ability to use insulin to access sugar as an energy source, neurons die. T3D-959 acts as a powerful insulin sensitizer.”

Didsbury said the company just closed an oversubscribed seed round this summer, which SEC filings indicate targeted $550,000, and just opened a Series A round. “We will be using those funds to do pre-clinical trials and a pilot clinical trial in Alzheimer’s disease,” he said.

For his part, Didsbury has assembled a supporting cast of science and pharmaceutical business veterans and an advisory board that includes a key developer of Alzheimer’s drug Aricept and the chief of neurology at Duke University Medical Center. The CEO has served in the C-suites of several pharma companies over the last two decades, including NovaTarg and GlaxoSmithKline.

“It has been a personal mission of mine for the last 25 years in the pharmaceutical industry to identify and develop a breakthrough medicine,” Didsbury said. “This is the culmination of that search.”

[Image credit: Flickr user GreenFlames09]

TAGGED:Alzheimer's Diseasehealth start-ups!
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

Midwest Health Startups: Making More Deals but Drawing Less Money

July 26, 2013

Biosimilars are “me-too” drugs, not generics

May 12, 2016
Image
eHealthMedical InnovationsMobile Health

The Potential (And Setbacks) of Telemedicine

November 10, 2016
Image
GeriatricsHospital AdministrationMedical EducationPublic HealthTechnology

Person-Centered HealthCare: At-Home Care is Key

March 8, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?